mhurhangee/ep-ind-claims huggingface dataset:
A turbocompressor assembly which is divided along an axis of a rotor into at least three sections (13, 18, 22): - a bearing section having at least one active magnetic bearing to support the rotor; - a motor section comprising a motor having a stator arranged along the axis of the rotor, where the stator encloses a circumferential motor gap which is formed between the stator and the rotor; - a compressor section having a compressor for compressing a cooling fluid; wherein the turbocompressor assembly further comprises: - a common gas-tight housing enclosing the rotor, the bearing section, the motor section and the compressor section; and - a cooling system having an inlet for supplying the pressurized cooling fluid to the bearing section and the motor section through a fluid channel positioned between the bearing section and the motor section; characterized in that the cooling system further comprises a throttling means positioned adjacent to the motor gap for limiting the flow of cooling fluid from the fluid channel to the motor gap. - a bearing section having at least one active magnetic bearing to support the rotor; - a motor section comprising a motor having a stator arranged along the axis of the rotor, where the stator encloses a circumferential motor gap which is formed between the stator and the rotor; - a compressor section having a compressor for compressing a cooling fluid; - a common gas-tight housing enclosing the rotor, the bearing section, the motor section and the compressor section; and - a cooling system having an inlet for supplying the pressurized cooling fluid to the bearing section and the motor section through a fluid channel positioned between the bearing section and the motor section;
Hydraulic drive system (10; 10') comprising at least one first actuator, a tank, a first nonreturn valve and a first and a second pump (40; 50), wherein the first pump has a constant displacement volume, wherein the second pump has an adjustable displacement volume, wherein a first fluid flow path starting from the tank runs via the first pump, further via a first control point, further via the first nonreturn valve, to a second control point, wherein the at least one first actuator is fluidically connected to the second control point, wherein the first nonreturn valve permits a fluid flow only towards the second control point, wherein a second fluid flow path leads from the tank to the second control point via the second pump, wherein pressurized fluid can be conducted from the first control point to the tank via an adjustable first orifice, wherein the first orifice is loaded in the opening direction by the pressure at the second control point, wherein the first and the second pump (40; 50) are or can be brought into a rotational drive connection to each other, wherein their relative direction of rotation is fixedly predefined, wherein the first orifice is loaded in the closing direction by a fixedly predefinable control force which is independent of an individual load pressure acting in the at least one first actuator, characterized in that the second pump is adjustable in two opposite directions from a position having a zero displacement volume, so that it can be operated optionally as a pump or as a motor with the same direction of rotation.
Singling apparatus for granular material, in particular seed, wherein the singling apparatus comprises a conveying device mounted in a rotatable manner in a housing, said conveying device conveying granular material from a receiving region into a dispensing region and cooperating with a housing wall or a guide element such that the number of conveyed grains of the granular material decreases from the receiving region to the dispensing region, wherein, in the dispensing region, an outlet opening is arranged, via which a grain of the granular material that is conveyed by the conveying device into the dispensing region can be discharged from the housing and can be transferred to a dispensing device, wherein the singling apparatus comprises a sensor, with which the number of grains of the granular material that are discharged from the housing and transferred to the dispensing device is able to be determined; wherein a measurement signal of the sensor is able to be transmitted to a control device, and wherein the control device is configured such that it controls or regulates the rotational speed of the conveying device on the basis of the measurement signal; and characterized in that the sensor is configured such that the number of grains discharged within a particular time period is able to be determined for a multiplicity of time periods, and wherein the control device is configured such that it uses a distribution, determined on the basis of measurement signals of the sensor, of the number of grains dispensed by the singling apparatus per time period to control or regulate the rotational speed of the conveying device.
A slat support and deployment apparatus comprising a master slat support and deployment assembly and a slave slat support and deployment assembly, the master and the slave slat support and deployment assembly (30, 31) each including an arm (33, 34) having a free end attachable to the same slat at spaced locations along its length for deployment and retraction of said slat in a direction generally parallel to a wing in response to simultaneous movement of said arms (33, 34), the master and the slave slat support assembly (30, 31) each including a coupling (35, 36) for attaching said free end of each arm to a slat, wherein the coupling (35, 36) that couples the free end of the arm of each slat support and deployment assembly (30, 31) to a slat is configured to allow movement of that slat relative to said free end of said arm of each slat support and deployment assembly (30, 31) during deployment and retraction of said slat, wherein the coupling (35, 36) that couples the free end of the arm of each slat support and deployment assembly (30, 31) to a slat is configured to allow movement of that slat relative to said free end of said arm of each slat support and deployment assembly (30, 31) in multiple directions, said multiple directions comprising rotation about a first, second and third axes, the first, second and third axes being at right-angles to each other.
A wavelength spectroscopy device comprising, on a substrate, a radiation module comprising an emission cell and a filter cell constituted by two mirrors (MIR1, MIR2; M1, M2) separated by a spacer membrane, the device being characterized in that the filter cell is made up of a plurality of interference filters (FP1, FP2, FP3; IF11-IF44), said emission cell comprises a plurality of emission sources, each of said sources being associated with one of said interference filters so that each of the emission sources faces one of the interference filters, a thickness of the spacer membrane is constant for a given interference filter and varies from one interference filter to another, and the spectroscopy device is for an analysis in transmission of a medium, said medium having to be situated, during analysis, between a detector and said radiation module.
An aqueous pharmaceutical solution composition comprising between about 20 mg/ml to about 100 mg/ml of at least one radioprotective α,β-unsaturated aryl sulfone and at least one cosolvent comprising polyethylene glycol, polypropylene glycol, polyglycerol, DMA, propylene glycol, glycerol, ethanol, sorbitol, isopropyl alcohol, or a combination thereof in an amount between about 25% and about 90% w/v, and at least one stabilizing agent comprising a water soluble Vitamin E derivative, wherein the composition has a pH within the range of about 7.0 to about 9.5.
A method of purifying a secreted TGF-β superfamily protein, said method comprising i. contacting a solution containing the secreted TGF-β superfamily protein with a Hydrophobic Charge Interaction Chromatography (HCIC) resin for obtaining a first eluate containing the secreted TGF-β superfamily protein. i. contacting a solution containing the secreted TGF-β superfamily protein with a Hydrophobic Charge Interaction Chromatography (HCIC) resin for obtaining a first eluate containing the secreted TGF-β superfamily protein.
An additive manufacturing method comprising: detecting a defect (264, 364) in a powder containment wall (158, 258, 358) formed using an additive manufacturing process, the powder containment wall (158, 258, 358) including a first surface that faces a powder containing region and a second surface that faces a substantially powder free region; generating a supplemental scan path that covers at least a portion of the powder containment wall (158, 258, 358) based on a location of the detected defect (264, 364); and controlling a consolidation device (16, 272), based on the supplemental scan path, to remedy the defect (264, 364). detecting a defect (264, 364) in a powder containment wall (158, 258, 358) formed using an additive manufacturing process, the powder containment wall (158, 258, 358) including a first surface that faces a powder containing region and a second surface that faces a substantially powder free region; generating a supplemental scan path that covers at least a portion of the powder containment wall (158, 258, 358) based on a location of the detected defect (264, 364); and controlling a consolidation device (16, 272), based on the supplemental scan path, to remedy the defect (264, 364).
An intracortical-detection device comprising: - at least one electrode designed to contact a group of neurons; - a first body, forming a surface designed to contact a portion of a cerebral region; - a first motor configured to move said at least one electrode with respect to said first body; and - a second motor, which is fixed with respect to the first body; and - a second body, operatively connected to said second motor, said first and second bodies being able to slide with respect to one another in a first direction (x), under the action of said second motor; - a crank (16; 90), which is coupled to said second body and can be driven in rotation by said second motor about a second direction transverse with respect to said first direction (x); and - constraint means (22, 24) designed to prevent the motion of said first body with respect to said second body in directions different from said first direction; characterized by further comprising sensor means (42,44,55) configured to generate an electrical signal indicating a pressure exerted by said portion of cerebral region on said surface; wherein said sensor means comprise transducer means (42, 44) arranged on said crank and configured to vary an own electrical quantity as a function of a deformation of said crank caused by the pressure exerted by said portion of cerebral region on said surface. - at least one electrode designed to contact a group of neurons; - a first body, forming a surface designed to contact a portion of a cerebral region; - a first motor configured to move said at least one electrode with respect to said first body; and - a second motor, which is fixed with respect to the first body; and - a second body, operatively connected to said second motor, said first and second bodies being able to slide with respect to one another in a first direction (x), under the action of said second motor; - a crank (16; 90), which is coupled to said second body and can be driven in rotation by said second motor about a second direction transverse with respect to said first direction (x); and - constraint means (22, 24) designed to prevent the motion of said first body with respect to said second body in directions different from said first direction; characterized by further comprising
Apparatus for filling containers, comprising - a linear-drive arrangement having a closed running path and a multiplicity of runners for accommodating and transporting the containers, - a multiplicity of stations, which are arranged on the running path, wherein the multiplicity of stations comprise at least one filling station (7.3) for filling the containers, and - a control unit, which is intended to drive, and to stop, the runners individually, - wherein the runners have sliding elements or rolling-contact bodies, which slide or roll on the running path, characterized in that - the apparatus is intended for filling containers with a liquid medium in the pharmaceutical sector, - the closed running path defines a circle and is arranged horizontally, and each runner has at least two mounts for accommodating the containers, - the running path comprises a driving region of the linear-drive arrangement as well as a running region, wherein the running region is arranged at an angle (α) to the driving region, and - the control unit is intended such that, at stations at which runners with liquid-filled containers start up again, it controls a start-up operation of the runners individually at a lower speed than in stations in which still-empty containers are being moved. - a linear-drive arrangement having a closed running path and a multiplicity of runners for accommodating and transporting the containers, - a multiplicity of stations, which are arranged on the running path, wherein the multiplicity of stations comprise at least one filling station (7.3) for filling the containers, and - a control unit, which is intended to drive, and to stop, the runners individually, - wherein the runners have sliding elements or rolling-contact bodies, which slide or roll on the running path, - the apparatus is intended for filling containers with a liquid medium in the pharmaceutical sector, - the closed running path defines a circle and is arranged horizontally, and each runner has at least two mounts for accommodating the containers, - the running path comprises a driving region of the linear-drive arrangement as well as a running region, wherein the running region is arranged at an angle (α) to the driving region, and - the control unit is intended such that, at stations at which runners with liquid-filled containers start up again, it controls a start-up operation of the runners individually at a lower speed than in stations in which still-empty containers are being moved.
A process for producing random numbers by means of a quantum random number generator, the process comprising the steps of: a) operating a multimode laser diode in high modulation bandwidth and depth by means of an electrical pulse driver that modulates the net gain continuously from positive to negative values and vice-versa; b) maintaining the net gain per round trip positive over a period longer than the round trip time of the cavity; c) maintaining the time net gain per round trip negative over a period longer than the round trip time of the cavity; d) detecting the resulting random beating pattern between the multiple modes in a) by means of a fast photodiode; e) obtaining random numbers by sampling subsequent pulses so as to produce a digitization of random amplitudes. a) operating a multimode laser diode in high modulation bandwidth and depth by means of an electrical pulse driver that modulates the net gain continuously from positive to negative values and vice-versa; b) maintaining the net gain per round trip positive over a period longer than the round trip time of the cavity; c) maintaining the time net gain per round trip negative over a period longer than the round trip time of the cavity; d) detecting the resulting random beating pattern between the multiple modes in a) by means of a fast photodiode; e) obtaining random numbers by sampling subsequent pulses so as to produce a digitization of random amplitudes.
Process for producing propylene random copolymers with an MFR 2 in accordance with ISO 1133 (230°C, 2.16 kg) in the range of 0.1 to 200 g/10min and an ethylene and/or C 4 -C 12 alpha-olefin comonomer content in the range of 1 to 15 wt% of the propylene random copolymer, said process comprises the steps of a) polymerising propylene and ethylene and/or a C 4 -C 12 alpha-olefin comonomer in a slurry reactor in the presence of hydrogen and a polymerisation catalyst system obtaining as slurry reactor product a first propylene copolymer component, the comonomer/propylene ratio being in the range of 2 to 40 mol/kmol, and the hydrogen/propylene ratio being in the range of 0.1 to 30 mol/kmol, b) transferring the slurry reactor product into a gas phase reactor c) further polymerising propylene and ethylene and/or a C 4 -C 12 alpha-olefin comonomer in the presence of said slurry reactor product, the polymerisation catalyst system and additional hydrogen, the comonomer/propylene ratio being in the range of 5 to 60 mol/kmol, and the hydrogen/propylene ratio being in the range of 2 to 200 mol/kmol, d) optionally recovering the so produced propylene random copolymer for further processing, said polymerisation catalyst system comprising (i) a Ziegler-Natta procatalyst and (ii) an organometallic cocatalyst and (iii) an external donor represented by formula Si(OCH 2 CH 3) 3 (NR 1 R 2) wherein R 1 and R 2 can be the same or different and represent a hydrocarbon group having 1 to 12 carbon atoms. a) polymerising propylene and ethylene and/or a C 4 -C 12 alpha-olefin comonomer in a slurry reactor in the presence of hydrogen and a polymerisation catalyst system obtaining as slurry reactor product a first propylene copolymer component, the comonomer/propylene ratio being in the range of 2 to 40 mol/kmol, and the hydrogen/propylene ratio being in the range of 0.1 to 30 mol/kmol, b) transferring the slurry reactor product into a gas phase reactor c) further polymerising propylene and ethylene and/or a C 4 -C 12 alpha-olefin comonomer in the presence of said slurry reactor product, the polymerisation catalyst system and additional hydrogen, the comonomer/propylene ratio being in the range of 5 to 60 mol/kmol, and the hydrogen/propylene ratio being in the range of 2 to 200 mol/kmol, d) optionally recovering the so produced propylene random copolymer for further processing, (i) a Ziegler-Natta procatalyst and (ii) an organometallic cocatalyst and (iii) an external donor represented by formula Si(OCH 2 CH 3) 3 (NR 1 R 2)
A method of identifying a metastatic castration resistant prostate cancer (mCRPC) patient with an improved response to taxane therapy compared to androgen receptor signaling-directed (ARS-directed) therapy comprising: (a) performing a direct analysis comprising immunofluorescent staining and morphological characterization of nucleated cells in a blood sample from the patient to generate circulating tumor cell data, wherein the direct analysis means the detection of the CTCs in the context of all surrounding nucleated cells present in the sample as opposed to after enrichment of the sample for CTCs prior to detection, and wherein the direct analysis comprises detecting the presence of an Androgen Receptor Variant 7 (AR-V7) in said cells, and (b) evaluating the CTC data to identify an mCRPC patient with an improved response to taxane therapy compared to ARS-directed therapy, wherein the presence of an Androgen Receptor Variant 7 in said CTCs identifies a mCRPC patient with an improved response to taxane therapy compared to ARS-directed therapy (a) performing a direct analysis comprising immunofluorescent staining and morphological characterization of nucleated cells in a blood sample from the patient to generate circulating tumor cell data, wherein the direct analysis means the detection of the CTCs in the context of all surrounding nucleated cells present in the sample as opposed to after enrichment of the sample for CTCs prior to detection, and wherein the direct analysis comprises detecting the presence of an Androgen Receptor Variant 7 (AR-V7) in said cells, and wherein the direct analysis means the detection of the CTCs in the context of all surrounding nucleated cells present in the sample as opposed to after enrichment of the sample for CTCs prior to detection, and wherein the direct analysis comprises detecting the presence of an Androgen Receptor Variant 7 (AR-V7) in said cells, and (b) evaluating the CTC data to identify an mCRPC patient with an improved response to taxane therapy compared to ARS-directed therapy, wherein the presence of an Androgen Receptor Variant 7 in said CTCs identifies a mCRPC patient with an improved response to taxane therapy compared to ARS-directed therapy
Electric motor for an elevator system, the electric motor comprising: a housing extending in a longitudinal direction along a longitudinal axis and a cover attached to a front face of the housing, the cover comprising an open space formed around the longitudinal axis and at least one electric connector (38, 40) electrically connectable to components of the electric motor and arranged within said open space; wherein the cover comprises a cylindrical outer wall extending circularly with an outer radius (R 1) around the longitudinal axis and a cylindrical inner wall extending coaxially with respect to the outer wall with an inner radius (R 2) around the longitudinal axis, the inner wall defining the open space; characterized in that the at least one electric connector (38, 40) is mounted to an inner side of the cylindrical inner wall facing the longitudinal axis. a housing extending in a longitudinal direction along a longitudinal axis and a cover attached to a front face of the housing, the cover comprising an open space formed around the longitudinal axis and at least one electric connector (38, 40) electrically connectable to components of the electric motor and arranged within said open space; wherein the cover comprises a cylindrical outer wall extending circularly with an outer radius (R 1) around the longitudinal axis and a cylindrical inner wall extending coaxially with respect to the outer wall with an inner radius (R 2) around the longitudinal axis, the inner wall defining the open space; characterized in that the at least one electric connector (38, 40) is mounted to an inner side of the cylindrical inner wall facing the longitudinal axis.
A method of controlling quality and quantity of posttranslational modification of a recombinantly produced polypeptide/protein (glycoprotein), wherein the posttranslational modification is selected from bG0 structures and bG1 structures, and wherein the polypeptide/protein (glycoprotein) production is in eukaryotic host cells, the method comprising the following steps: a) cultivating the eukaryotic cells in a suitable medium under conditions which allow the expression of the polypeptide/protein, wherein the content of the dissolved CO 2 (pCO 2) in the medium is at a first value during the initial growth phase of the eukaryotic cells, allowing the eukaryotic cells to grow, and b) increasing or decreasing the content of the dissolved CO 2 (pCO 2) in the medium during the production phase of the eukaryotic cells to a second value. a) cultivating the eukaryotic cells in a suitable medium under conditions which allow the expression of the polypeptide/protein, wherein the content of the dissolved CO 2 (pCO 2) in the medium is at a first value during the initial growth phase of the eukaryotic cells, allowing the eukaryotic cells to grow, and b) increasing or decreasing the content of the dissolved CO 2 (pCO 2) in the medium during the production phase of the eukaryotic cells to a second value.